Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692782 · ClinicalTrials.gov registry record · Phase 2
Adult Attention Deficit Hyperactivity Disorder
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 341
- Enrollment target
NCT01692782: Completed Phase 2 study, sponsored by Sumitomo Pharma America.
NCT01692782 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 341 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (156% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01692782, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 341 participants
- Enrollment target
Study Summary
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
Primary Outcome
The ADHD RS-IV with adult prompts is an 18 item scale based on the DSM IV TR criteria for ADHD that provides a rating of the severity symptoms. Scoring is based on a 4 point Likert-type severity scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Clinicians scored the highest score that was generated for the prompts for each item. The ADHD rating scale total score is defined as sum of all 18 item scale scores.
Interventions
- DRUG Placebo
- DRUG SEP-225289
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT01692782 record still lists
NCT01692782 is an interventional study that assigns participants to a tested intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (156% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01692782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01692782 about?
NCT01692782 is a clinical study titled "Adult Attention Deficit Hyperactivity Disorder". A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
What is the current status of trial NCT01692782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 341 participants. The study started on 2012-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01692782?
The interventions under investigation include: Placebo (DRUG), SEP-225289 (DRUG).
Who is sponsoring clinical trial NCT01692782?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01692782's enrollment target sits among peer trials
341 137th of 2000 higher than 1,864 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia